Peabody Energy Corporation is rated a Buy due to recent share price weakness presenting a good entry point. The company benefits from rising coking coal prices and the operational ramp-up of its Centurion project in Australia, which is expected to boost earnings significantly. Despite a Q1 2026 EBITDA decline caused by ramp-up challenges, Peabody's stock remains attractively valued with a forward EV/EBITDA of 3.7, or about 2 on aggressive estimates, offering potential upside amid commodity and operational risks.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
Noble Corporation reported weaker-than-expected revenue and earnings per share for Q2 2026 due to vessel suspensions and contract completions. Despite lowering its full-year 2026 guidance, the company maintains a strong backlog of $6.8 billion and ri...
Bitcoin fell more than 3% to around $63,494, hitting a 10-day low as tech stocks tied to AI plunged, notably South Korea's KOSPI dropping over 10%. This sell-off spread to digital assets, with Ethereum, Solana, and XRP also declining. Market uncertai...
CoinMarketCap's Altcoin Season Index increased to 53, indicating a slight improvement in altcoin performance relative to Bitcoin. However, this level remains below the 75 threshold that signals a full altcoin season, keeping the market in a neutral s...
Unilever reported its strongest quarterly volume growth in more than ten years, with underlying sales rising 5.8% in Q2, surpassing analyst expectations. Sales volumes increased 5.5%, and revenue reached €13.05 billion, beating forecasts. The company...
